Provided by Tiger Trade Technology Pte. Ltd.

BioAge Labs Inc.

9.48
-0.2100-2.17%
Post-market: 9.800.3200+3.38%19:34 EDT
Volume:453.45K
Turnover:4.35M
Market Cap:435.10M
PE:-4.00
High:9.92
Open:9.78
Low:9.48
Close:9.69
52wk High:25.96
52wk Low:4.42
Shares:45.90M
Float Shares:37.58M
Volume Ratio:0.81
T/O Rate:1.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3710
EPS(LYR):-2.2432
ROE:-28.21%
ROA:-18.47%
PB:1.16
PE(LYR):-4.23

Loading ...

BioAge Labs price target lowered to $20 from $23 at Morgan Stanley

TIPRANKS
·
Aug 07

Analysts’ Opinions Are Mixed on These NA Stocks: BioAge Labs, Inc. (BIOA) and Fiserv (FISV)

TIPRANKS
·
Aug 07

BioAge Labs Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Aug 06

BioAge Labs, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate

Benzinga Earnings
·
Aug 06

BioAge Q2 FY26 Net Loss Widens to $26.1 Million; R&D Expenses Rise to $24.37 Million

Reuters
·
Aug 06

Bioage Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
Aug 06

BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates

GlobeNewswire
·
Aug 06

Analysts Offer Insights on NA Companies: Central Bancompany (CBC) and BioAge Labs, Inc. (BIOA)

TIPRANKS
·
Aug 03

BioAge Labs Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Aug 03

Analysts Have Conflicting Sentiments on These NA Companies: BioAge Labs, Inc. (BIOA) and adidas AG (GB:0OLD)

TIPRANKS
·
Aug 01

Small U.S. Stocks Close Lower; BioAge Labs Posts Biggest Loss

Dow Jones
·
Aug 01

BioAge Labs is Maintained at Buy by Needham

Dow Jones
·
Aug 01

Roth MKM Reaffirms Their Buy Rating on BioAge Labs, Inc. (BIOA)

TIPRANKS
·
Aug 01

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

BioAge Labs price target lowered to $25 from $36 at Roth Capital

TIPRANKS
·
Aug 01

Buy Rating Reaffirmed on BioAge: Sell-Off Seen as Overdone Amid Validated NLRP3 Platform and Triple-Digit Upside Potential

TIPRANKS
·
Aug 01

BioAge Labs pullback after ZEUS data ‘seems overdone,’ says Citi

TIPRANKS
·
Aug 01

BioAge Labs price target lowered at Jefferies after Novo trial miss

TIPRANKS
·
Aug 01

BioAge Labs price target lowered to $50 from $60 at Oppenheimer

TIPRANKS
·
Aug 01